Biogen Inc. (BIIB) Earnings Call Transcript & Summary

May 3, 2022

NASDAQ US Health Care Biotechnology earnings 62 min

Earnings Call Speaker Segments

Michael Hencke

executive
#1

Thanks. Good morning, and thanks for joining us for Biogen's first quarter 2022 earnings call. Before we get started, I'd ask everyone to visit the investors section of biogen.com, where you can locate the earnings release and the related financial tables, which include our GAAP financial measures along with a reconciliation of the GAAP to non-GAAP financial measures we'll be discussing today. Tables one and two contain our GAAP financials, and a reconciliation of our GAAP to non-GAAP financial results appears in table four. In our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage the business internally; we've also put slides on our website that accompany the discussions related to this call. I want to note that we'll be making forward-looking statements, which rest on our current expectations and beliefs. Certain risks and uncertainties apply to these statements, and our actual results may differ materially. For additional detail, I'd encourage you to review the risk factors discussed in our SEC filings. Joining me on today's call are our Chief Executive Officer, Michel Vounatsos, Dr. Priya Singhal, Interim Head of Research and Development, and our CFO, Michael McDonnell. As a reminder, during the Q&A portion of the call, we kindly ask that you limit yourself to one question. I'll now hand the call over to Michel.

Michel Vounatsos

executive
#2

Thank you, Mike. Good morning to all of you, and I appreciate you being here with us; throughout the first quarter, we've kept moving forward on the key goals of our core business. Mike and Priya are going to walk through how we performed this quarter and what's been happening lately in R&D, and I'll be concentrating on our strategy along with the operational matters that need attention in the near term. To begin, I'd like to offer some thoughts about the national coverage determination that CMS recently issued concerning amyloid beta-targeted therapies for Alzheimer's disease; through this ruling, access to Aduhelm is effectively being denied to every Medicare beneficiary. This final NCD leaves us deeply disappointed, and because of it, we're going to wind down the vast majority of the commercial operation we built for Aduhelm; a small set of resources will remain so we can administer patient access programs, among them a no-cost drug program that continues for those already receiving treatment here in the U.S. We anticipate keeping up our funding for certain regulatory and R&D work tied to Aduhelm, which covers continuing our EMBARK re-dosing study as well as kicking off ENVISION, our phase 4 post-marketing requirement study. What we do next with regard to Aduhelm could be shaped by data readouts for this antibody class that are due soon, and also by more discussions with the FDA and CMS. At the same time, we're dedicated to collaborating closely with Eisai on the possible launch of lecanemab. Our attention now turns ahead as we push forward on the wider pipeline, which includes lecanemab and zuranolone, while running our base business and allocating our capital in whatever way best serves shareholders. We're aware that a number of near-term hurdles confront Biogen. Those hurdles — generic erosion affecting Tecfidera, competition facing Spinraza, biosimilars in anti-TNF, and a shrinking profit share from Rituxan in the U.S. — are simply inherent to the life cycle of the biopharmaceutical industry, and we think launches of potential new products like lecanemab, zuranolone and further biosimilars could help bring the company back to growth eventually. Beyond that, we foresee the possibility of another growth driver in the mid- to late twenties across other areas, for instance stroke, lupus, and Parkinson's disease. Naturally, we'll also be chasing new business development possibilities. That said, since ours is a long product cycle business, and considering what CMS decided, we know there's more work to be done right now to give better clarity and visibility regarding the company's future. Let me walk you through the priority actions we're putting into place at this moment. First, we're sharpening our focus on R&D prioritization, aiming to maximize the probability of success, which Priya will talk about in more detail. Key data readouts anticipated in 2022 will help shape this prioritization process in part. When it comes to Alzheimer's disease, we and Eisai intend to finish the rolling submission for lecanemab through the accelerated approval pathway in the U.S. sometime in the second quarter of this year. On top of that, we're expecting a readout from the phase 3 Clarity AD confirmatory trial for lecanemab in the fall. Given what the study showed, we intend to file for complete FDA approval during Q1 of 2023, and lecanemab could become the first anti-amyloid antibody granted full approval for Alzheimer's disease here in the U.S. Within neuropsychiatry, we're partnering with Sage to move zuranolone forward as a potentially important new choice for MDD and PPD. We kicked off the rolling submission for zuranolone in MDD not long ago and anticipate wrapping up that filing during the latter half of 2022. We're also eager for the phase 3 SKYLARK readout in PPD, which should arrive around the middle of this year, with a corresponding PPD filing expected in early 2023; separately, still in neuropsychiatry, a phase 2 readout for BIIB104 in cognitive impairment associated with schizophrenia should come around mid-2022. Next, we'll put in place further cost-cutting and productivity steps that go beyond the initiatives we already told you about, so our cost structure lines up better with our revenue base. Among these steps will be a sizable wind-down of the commercial organization behind Aduhelm, plus other savings, even as we keep putting money into promising pipeline and commercial prospects. Third, we're pursuing international growth, concentrating on major emerging markets including China along with selected markets across Latin America and the Middle East; that involves carrying on the Spinraza launch and could extend to local business development efforts. Fourth, we intend to reignite growth in our biosimilars operation. Even though our anti-TNF portfolio has probably moved beyond the high point of its life cycle, we have 4 additional programs in development right now, and soon we'll be getting ready to introduce BYOOVIZ, which references Lucentis, in the US over the next few months. Our fifth near-term priority concerns capital allocation. Biogen is lucky to hold a solid balance sheet, with $4.8 billion in cash at quarter's end and only modest net debt, plus robust cash flow generation. Looking ahead, we'll keep directing cash toward efforts meant to open up incremental revenue growth opportunities, while still giving cash back to shareholders via share repurchases. To sum up, the difficulties this company has confronted across the past 12 months have been considerable; we're dedicated to leveraging every strength we possess, among them our talent, our commercial portfolio, our manufacturing capabilities, our pipeline — which contains 10 programs in phase 3 or filed — and naturally, our solid balance sheet, in order to produce the performance people expect from us. Let me close by noting that leading this remarkable company through such a demanding stretch, and collaborating closely with so many committed and gifted colleagues, has been an honor. Everything we've accomplished makes me extremely proud. I'd like to express my thanks to the board of directors and to my colleagues for standing behind me throughout this time. My departure comes at a moment full of promise for Biogen, with remarkable room to create value, and I'm eager to collaborate with the person who follows me to ensure a seamless handover. At this point, I'll hand things over to Priya so she can share news about what we've recently achieved in R&D.

Priya Singhal

executive
#3

Thanks, Michel, and hello everybody on this call. Michel already noted that we're sharpening how we prioritize R&D dynamically, which is meant to secure a pipeline that lasts and can support Biogen's ambition of a portfolio spanning multiple franchises. Our R&D spending will stay disciplined, and we'll chase fresh, innovative external chances whose risk-reward profile may differ, covering opportunities inside our main neuroscience therapeutic areas plus chosen bets in adjacent therapeutic fields; emerging scientific data, along with internal and external readouts, will guide this approach. Under this broader prioritization plan, we might decide to speed up, halt, sell off, or partner some programs; on top of that, we'll keep building important capabilities like functional genomics, patient identification, novel modalities, biomarkers, and clinical outcome measures. The aim is cutting risk, speeding clinical development, and raising the odds of success in reaching positive proof of concept. Now I'll walk through the quarter's R&D highlights. Beginning with Alzheimer's disease, besides ongoing progress on the lecanemab U.S. During last March's yearly AD/PD conference, Eisai presented findings from the filing and the phase 3 trial showing that in the core phase 2b research, lecanemab therapy led to a reduction in brain amyloid—dependent on both dose and duration—as detected through PET SUVR. Furthermore, this decline in brain amyloid corresponded with changes in two important peripheral biomarkers tied to amyloid and tau pathology. To be precise: an increase in the plasma Abeta 42/40 ratio and a decrease in plasma phospho-tau181. Additionally, these biomarker changes aligned with clinical improvement, as assessed by the shift from baseline in the Clinical Dementia Rating Sum of Boxes. Importantly, though, these peripheral biomarkers started gradually reversing once lecanemab treatment stopped at the close of the core study, which hints that halting dosing too early could permit Alzheimer's disease pathology to reaccumulate. Eisai also shared further ARIA information from the lecanemab phase 2b study. That covered ARIA-E incidence in the open-label extension, where ARIA-E appeared in under 10% of participants on 10 mg/kg lecanemab biweekly, alongside a symptomatic ARIA rate under 2%, matching the core study. Through the bigger phase 3 Clarity AD study, we expect to further characterize lecanemab's safety and efficacy. At the moment, Biogen and Eisai are looking at subcutaneous dosing through a sub-study within the Clarity AD open label extension. In that sub-study, injections given under the skin will be compared with infusions delivered intravenously. On top of that, the AHEAD 3 to 45 study continues, testing lecanemab in individuals who have preclinical Alzheimer's disease or who have not yet developed cognitive impairment; that trial began in 2020. Beyond lecanemab, Biogen continues its pursuit of novel therapies targeting various molecular targets in Alzheimer's disease. This work involves active planning for a phase 2 study of BIIB080, our tau ASO, along with launching dosing in the phase 1 study of BIIB113. BIIB113 works as a small molecule inhibitor targeting O-GlcNAcase, or OGA — an enzyme thought to drive the removal of the O-GlcNAc post-translational modification on the tau protein. Through OGA inhibition, our goal is to boost tau's O-GlcNAcylation, which could potentially block tau aggregation and in turn slow clinical decline. As Michel noted, alongside aducanumab we're still gathering data from our EMBARK redosing study, while also preparing to launch the Aduhelm phase 4 post-marketing requirement studies within ENVISION. Turning to neuropsychiatry, Biogen and Sage said recently that we've begun the rolling submission of an NDA to the FDA for zuranolone in MDD. We anticipate finishing that filing during this year's second half. We were also pleased to share that the zuranolone phase 3 CORAL study in major depressive disorder hit both its primary endpoint and key secondary endpoint. CORAL was a randomized, blinded trial built to evaluate how quickly patients respond when zuranolone 50 milligrams is started together with an open-label standard of care antidepressant, or ADT, versus placebo started together with ADT, gauged by change from baseline on the 17-item Hamilton Depression Rating Scale. Top-line results demonstrated that zuranolone started alongside ADT produced a statistically significant drop in depressive symptoms at day three — the primary endpoint and earliest time point measured — and also across the entire two-week treatment period, compared with placebo started alongside ADT. When it came to how well patients handled zuranolone, tolerability was generally good, and most of the adverse events that emerged during treatment were classified as either mild or moderate. Turning to MDD, we now have four randomized controlled trials with positive results for zuranolone in total, along with useful insights regarding repeat treatment that emerged from Shoreline, which is a sizable prospective naturalistic study conducted in MDD. Even though each of these trials was designed to address a distinct set of questions, what we see is a consistent profile for zuranolone that includes a swift decrease in depressive symptoms when compared with standard of care antidepressants. We also see a tolerability profile that stays consistent, with few patients discontinuing because of adverse events, and with no weight gain, sexual dysfunction, or suicidal ideation observed. What this offers is a brief treatment course that potentially can be taken as needed, along with a flexible approach to treatment that may give HCPs and patients additional optionality. This builds on favorable results we've seen from the phase 3 ROBIN trial of zuranolone for postpartum depression. By the middle of this year, we expect data from the phase 3 SKYLARK study in PPD, and a submission for PPD should follow in early 2025. There's real promise in offering patients who struggle with depression an oral antidepressant that acts quickly, is well tolerated, delivers lasting benefit and works through a novel mechanism. Turning to ALS, we've said before that the phase 3 VALOR trial of tofersen in SOD1 ALS — an uncommon inherited subtype of the disease — failed to hit its primary endpoint, which was a statistically significant shift on the ALSFRS-R at week 28 compared with placebo. Across several secondary and exploratory endpoints, we did see indications that disease progression had slowed. When the NEALS meeting takes place in June, we plan to present combined data from the phase 3 VALOR trial, plus a new interim assessment of its continuing open-label extension. That interim assessment includes SOD1-ALS participants who were able to be tracked for at least 12 months from the point VALOR started. Longer-term results related to function, strength, quality of life, and survival will also be presented. Recruitment is still underway for ATLAS, a trial assessing tofersen in pre-symptomatic individuals carrying a confirmed SOD1 mutation, and we are likewise backing the worldwide tofersen expanded access program, which so far encompasses roughly 120 individuals with SOD1-ALS across over 12 countries. We are additionally staying in dialogue with regulators regarding possible subsequent steps for tofersen. As is evident, 2022 stands as a significant year for R&D at Biogen, with multiple notable milestones anticipated as we keep moving forward a varied pipeline holding 32 clinical programs altogether, 10 of which sit in phase 3 or are undergoing filing. Among these milestones are major regulatory submissions, mid to late-stage data readouts spanning both Alzheimer's disease and neuropsychiatry, launching late-stage trials in Parkinson's disease, and kicking off a pivotal trial in cutaneous lupus erythematosus, alongside continued enrollment for 2 phase 3 lupus programs in SLE, plus mapping out what comes next for the BIIB131 stroke program; to wrap up, the steps we are taking should, in our view, make it possible to bring a number of potentially first-in-class and best-in-class molecules to patients battling illnesses with considerable unmet need. At this point I'll hand the call to Mike.

Michael McDonnell

executive
#4

Thanks, Priya, and hello everybody. I'll walk through several important points regarding how we performed financially this quarter, and then go over the guidance we're giving for the whole of 2022. Just so we're clear, every financial comparison is against the same period a year earlier, except where I say otherwise. First quarter total revenue came to $2.5 billion. Revenue from our MS business, which includes Ocrevus royalties, reached $1.6 billion. Generic competition in the US keeps weighing on Tecfidera, and pricing pressure from outside the US also hurt it. Vumerity posted $128 million in global revenue for the first quarter. We like how Vumerity is progressing in the US, and we're moving along well toward bringing it to as many as 20 markets beyond the US during this year. Tysabri's worldwide revenue rose 3%. Within the US, favorable pricing gave TYSABRI revenue a lift that outweighed a slight drop in volume. Beyond the US, we were happy to observe patients continuing to grow. Interferon's global revenue fell 23%, which reflects the ongoing move away from injectable platforms toward oral or high-efficacy treatments. Now turning to SMA, Spinraza's global revenue dropped 9%. In the US, although positive channel dynamics drove a 10% revenue increase, it was encouraging that new patient starts hit their highest level in over two years, while discontinuations kept slowing relative to the prior quarter. Outside the US, the revenue decline was mainly due to shipment timing in certain markets, competition, and unfavorable currency effects, partially offset by strong initial uptake in China, as that marked the first full quarter after national reimbursement there. Spinraza's global revenue rose 7% versus Q4 of 2021, supported by solid sequential performance outside the US and some seasonal dynamics in the US. Moving to biosimilars, revenue fell 5%. While our volume grew, that gain was more than offset by pressure on pricing and negative movement in foreign exchange. We completed the transaction in April to sell off our ownership interest in the biosimilar joint venture. Just to reiterate, the financial dynamics surrounding the anti-TNF and ophthalmology programs are expected to stay largely unchanged. In addition, we are preparing to introduce BYOOVIZ in the United States over the coming months. We expect that rollout to be gradual, with a more substantial revenue impact starting in 2023. Overall, we anticipate that biosimilars revenue for the entire year will decline relative to last year, driven by pricing pressure across Europe. Revenue for anti-CD20 as a whole increased 3%, since greater Ocrevus royalties were partially counterbalanced by Rituxan sales that keep shrinking amid biosimilar competition. During the first quarter, gross margin was adversely affected by a $275 million charge related to Aduhelm inventory write-offs, along with approximately $45 million in charges for idle capacity. It's important to note that Eisai's share of those charges is reflected in the collaboration profit sharing line. Moving on to expenses and the balance sheet: non-GAAP R&D expense for Q1 was $552 million. Non-GAAP SG&A amounted to $635 million, and that figure includes roughly $80 million connected to Aduhelm. Eisai's share of these costs is likewise recorded in the collaboration profit sharing line. In Q1, collaboration profit sharing reduced our net operating expense by $117 million. That number includes about $182 million that came back to us as reimbursement from Eisai, and it was partly reduced by $64 million in net profit-sharing expenses related to the Samsung Bioepis arrangement. Operating cash flow for Q1 was approximately $162 million, which was dampened because some payments fell at inconvenient times. We spent $58 million on capital expenditures, putting free cash flow at roughly $104 million. When the quarter ended, our debt stood at $7.3 billion, we held $4.8 billion in cash and marketable securities, and net debt was $2.5 billion. Subsequently, selling our JV equity to Samsung Biologics generated around $1 billion. Additionally, the $1 billion revolving credit facility we have remained untouched as of the quarter's close. Taking everything into account, our financial standing remains quite robust, and we have considerable cash reserves along with the financial flexibility needed to invest in expanding the business over the longer horizon. Let me now turn to the revised guidance we're providing for the entire 2022 year. Our revenue outlook for the full year stays at $9.7 billion-$10 billion, and that figure accounts for the U.S. dollar's appreciation between January first and April twenty-ninth, which we estimate creates a currency-related drag of roughly $120 million after accounting for hedging activities. Likewise, we're holding steady on our full-year non-GAAP diluted EPS guidance of $14.25-$16, even with the $0.76 hit from Aduhelm inventory write-offs and an additional impact of about $0.35 resulting from the dollar's strengthening that I mentioned earlier. When we gave our earlier forecast, we didn't factor in either the inventory write-offs or the currency headwinds. However, in our view, the extra cost actions we're announcing today, combined with stronger results from our core operations, should mostly cancel out those effects. For this outlook, we're still expecting Rituxan sales to keep falling because of biosimilar rivals, and Tecfidera revenue in the U.S. to keep shrinking as generics come in. We're also still building in the possibility that Tecfidera generics could arrive in the E.U. Looking ahead to Q2 2022, our gross margin percentage should come in lower than what we saw in 2021. Two things drive that: less revenue from those high-margin offerings, plus the charges tied to Agile home inventory. Keep in mind this outlook already takes into account the first wave of extra cost-cutting and productivity steps that Michel went over. We think these extra steps will save roughly $500 million a year. That comes on top of the programs we already told you about, which were aimed at about $500 million in yearly savings as well. So altogether, we're looking at around $1 billion in expected annualized savings, and some of that money will go back into strategic initiatives over the next few years. For non-GAAP R&D expense, our expectation is $2.2 billion to $2.3 billion, the same as what we guided before. Non-GAAP SG&A expense should land between $2.3 billion and $2.4 billion, down from the $2.5 billion to $2.6 billion we previously guided, and that reflects the added cost cuts I just described, which we anticipate will hit mostly in Q3 and Q4. This outlook is based on the assumption that FX rates from April 29 will stay in place through the rest of the year, after accounting for hedging, and it doesn't factor in any additional appreciation or depreciation of the dollar during the year. We're assuming that, over the course of the year, we'll draw on part of the $2.8 billion still available under our share repurchase authorization. Additional key assumptions behind this guidance can be found in our press release. To wrap up, we kept advancing our core business objectives during this quarter, and our attention now sits on a group of near-term operational priorities that we think can generate value creation over time. At this point, we'll open the call for questions.

Matthew Harrison

analyst
#5

Excellent. Good morning, and thank you for taking my question. Michel, I was hoping you might share your thoughts on the timing of the CEO transition we're seeing here, and also on what the board is seeking in a successor. Wishing you the very best through this change. Thank you.

Michel Vounatsos

executive
#6

Thanks, Matthew. As you know, 5.5 years is a solid term. Looking back at my career, that was roughly how long I spent in each of my major roles. I've put in a great deal, and I'll keep doing so as a priority throughout this transition to back the team so we can keep delivering. We reaffirmed our guidance today. Business momentum is going as well as it possibly could, even with the competition and the life cycle events we're up against; we're eager about the readouts ahead and, you know, with Aduhelm and the anti-amyloid, that story is still unfolding. It will keep going, and I'm really enthusiastic about the chance to have new readouts in that area that will best inform, you know, everything we've heard, including decisions. A CEO transition is a natural occurrence, and is there ever a perfect moment? I'm not certain. I believe that after five and a half years, while we have a strategy that's quite visible to all of you as a specialized neuroscience company, with some immuno assets that matter a lot and are in phase 3, along with the biosimilars and the digital health, I think the company is well positioned; it's good at some point to have someone else come in with the board's support and essentially revisit the assumptions. I think that will benefit everyone involved. My focus, again, will be on the company. It isn't about me, it's about the company, about the team, and about a smooth transition. Business continues. I'll be meeting all of you in the coming days, in person in Boston, in New York. I'll be traveling with my team in Asia at the end of the week to meet our key partners and potential future partners and support our team and meet with PMDA as well. The business continues, and I will be at the top of it until the last second.

Umer Raffat

analyst
#7

Hello, everyone. I really appreciate the opportunity to ask something. Let me zero in on expenses for a moment, and what I'm really attempting to figure out is how much money is actually being saved. I'm a bit puzzled since the SG&A outlook was lowered, yet SG&A itself was reduced, while the total guidance stayed the same. Perhaps an easier framing is: over the medium term ahead, where exactly are we going with OpEx? I recall back when I began covering Biogen, the company led in MS. Marketed MS revenues exceeded $4 billion, yet SG&A amounted to just $1 billion. Today, marketed MS revenues stand at $5 billion, so somewhat greater, but SG&A has reached $2.5 billion. Naturally, there are biosimilars and Spinraza in the mix, and I'm not claiming $2.5 billion will fall to $1 billion, but might we witness a meaningful SG&A rebasing across the business? Thanks a lot.

Michel Vounatsos

executive
#8

Yes, Umer, this is Mike speaking. Thanks for asking. So the savings we referred to earlier — that extra $500 million on a run-rate basis — is mostly going to be connected to the Aduhelm infrastructure. On our prior call, we noted we'd originally anticipated roughly a $400 million figure for 2022. Clearly, that's going to be reduced by a meaningful amount. Within the SG&A guidance, where we lowered it by approximately $200 million, that accounts for a considerable portion of it. On top of that, we'll certainly be examining certain non-revenue-facing areas within G&A and elsewhere so we can reach that run rate. As stated during our prepared remarks, it's possible we'll put some part of that $500 million in savings toward future growth initiatives, with the overarching aim being a return to growth. Finally, I'd note that on the guidance front, we managed to reaffirm it despite the inventory write-offs and currency headwinds we encountered, and that came down to two factors. First are the cost initiatives, and second, the top line did slightly better than what we'd initially anticipated when the year began. I'd highlight Spinraza MS, along with the CD20s, as performing somewhat more strongly than we'd expected.

Michael McDonnell

executive
#9

When you look at how the cost reductions and the top line interact, each of those two is responsible for roughly 50% of what lets us keep EPS flat. We are going to keep making whatever expense adjustments are required so that they match the way revenue is trending for the business, and I hope that gives you a bit of useful context.

Michel Vounatsos

executive
#10

Two things I'd like you to think about, Umer. First, when you first took over coverage of us, our operations were almost entirely within the United States, all right? That has changed. Second, back then the category contained only a handful of DMTs, whereas today it is incredibly packed, and Biogen continues to hold the top position worldwide across all of them — SMA, MS, and anti-TNFs in Europe. That requires real muscle and, clearly, skill. We have, you know, achieved enormous strides when it comes to leveraging digitization and other approaches to engagement, but we hear you; on top of that comes the spending we undertook on Aduhelm, which we are now removing.

Robyn Karnauskas

analyst
#11

Hello, and thanks for letting me ask. For my first question, that's directed at Priya. You brought up how fresh findings regarding lecanemab indicate that halting treatment might lead to a cognitive downturn. Could you share any additional details on what you believe causes that, and do you see a distinction in how it works compared with the medication from Eli Lilly? There's one more item — you also brought up the possibility of selling off some products. I'd like to hear more about which ones you meant. Thank you.

Michael McDonnell

executive
#12

Priya?

Priya Singhal

executive
#13

Absolutely, and I appreciate the question. To start, I'll address lecanemab. The information I was pointing to comes from the gap period within the open-label portion, after which came the open-label extension of that phase 2 trial. What this demonstrates, I believe, is that our scientific understanding regarding the optimal length of treatment is still developing. That's the key takeaway here. This area is changing. Two biomarkers were involved — the Abeta 42/40 ratio and plasma phospho-tau181 — and in both we observed a reversal, moving in the undesired direction. How are we responding? Eisai is genuinely taking the lead here, since they are evaluating how maintenance therapy might be implemented, and they're doing so within their open-label extension in the phase 2 study. Additional data will likely emerge in the coming period as they gain further understanding. Now, regarding donanemab, since you asked for a comparison, I can only address what has been publicly disclosed. What remains unseen, I believe, is the impact of extended follow-up; we lack a comparable picture of what occurs with amyloid plaques or phospho-tau after lecanemab is discontinued. Such information would matter if we're to draw a fair comparison. Currently, what we believe, together with Eisai, and what the evidence suggests, is that halting treatment too early may produce a reversal. I hope that addresses that portion of your question. Your second point concerned divestiture. Let me take a broader view and say that we are examining our full portfolio — our R&D portfolio — and making integrated prioritization decisions. What does that mean? It means we're evaluating our disease areas and therapeutic areas, identifying where we lead, where substantial internal expertise resides, and prioritizing in line with that while acting as responsible stewards of our resources. This is partly shaped by both internal and external readouts. For instance, we recently submitted our filing for zuranolone. That's a highly encouraging milestone for us in neuropsychiatry, and we anticipate an upcoming readout for BIIB104, which targets cognitive impairment associated with schizophrenia. We'll see what those results reveal. Once again, we'll anchor to areas where we've had success and hold expertise, and build around them. The same applies to lupus. We have three programs in lupus, and we'll keep expanding those areas as readouts and data come in. We might also consider expanding indications. Truly, everything is on the table, and we're striving to be highly disciplined about integrated prioritization and methodology. Within that framework, some assets may exist where we believe they could be better utilized through partnering or by externalizing them. That's the sense in which I used the word divest. I hope that clears things up. It represents merely a single piece of a far broader R&D approach that is synchronized and integrated. Thanks.

Michael McDonnell

executive
#14

Operator, let's go ahead and take the following question, please. Operator, if you happen to be on the line, we aren't able to hear you. All right, it seems we're running into some technical issues; we'll attempt to get back onto the call.

Priya Singhal

executive
#15

We can check if Robyn had. We heard the response.

Michael McDonnell

executive
#16

Yes, this is the Biogen team. We've rejoined the call.

Salveen Richter

analyst
#17

Morning. I appreciate you taking my question. When it comes to the way you allocate capital to fuel growth, where does business development rank as a priority?

Michael McDonnell

executive
#18

Hi Salveen, this is Michael McDonnell, and I really appreciate the question. Business development, you know, has been a priority and remains one. We've got a pipeline we're feeling good about, and we'll keep seeking to add to it via business development deals, just as we've done before. At the same time, you know, we'll keep giving capital back to shareholders. It's going to remain a balancing act, and, you know, business development has been a priority and will stay one.

Michael Yee

analyst
#19

Thanks. I appreciate that. To build on what Michel and Priya said regarding how we prioritize the R&D portfolio, would it be fair to say that you'd look at anything — divesting, partnering, out licensing, bringing things in — but the idea being that nothing is off the table, even when it comes to product lines or franchises, that the entire portfolio in every respect is fair game? Could you make that clear? Thanks very much.

Priya Singhal

executive
#20

Thanks, Michael. Yes, I'd say that in every area, science will be our guide, along with integration and getting the most value for patients, you know, in diseases with significant unmet need. I believe we'd weigh every option, but science must be what drives us, and that's how those evaluations would be conducted. Yeah, exactly, like you mentioned.

Michael Yee

analyst
#21

Should commercialization, businesses, and franchises also be part of that?

Michel Vounatsos

executive
#22

For some, maybe, though not in every case. On a handful of priorities, my view is that Biogen will stay in the stronger position, while on others we'll be willing to explore partnering. That's a call for Priya and the team to make, with backing from the company's governance.

Cory Kasimov

analyst
#23

Hi there, good morning, everyone. Thanks for taking my question. I'd like to know, what does pulling back substantially on Aduhelm's commercial infrastructure indicate, if anything at all, regarding what you anticipate from the phase 3 lecanemab data? Or is the wait simply too lengthy before securing full approval, regardless of whether lecanemab succeeds in Clarity AD? On that note, could you remind us how your commercialization duties in that area might differ from those with Aduhelm? Thank you.

Michel Vounatsos

executive
#24

The phase 3 readout is expected in the fall of this year. Together with a partner, in full alignment, we are working through the operational specifics beyond lecanemab. Given the timing, maintaining such a sizable team over such an extended period would not make sense. In my view, it's the correct call. The groundwork laid on the infrastructure remains in place, and the whole class certainly stands to gain a great deal going forward, yet regrettably, we were unable to keep that team for so many months. In my view, it's the correct call. To be clear, our view on lecanemab remains unchanged.

Marc Goodman

analyst
#25

Yes, hello. Picking up where we left off on the R&D discussion. From the perspective of those outside the company, I believe the perception has been that our pipeline has tended to carry rather high risk alongside high reward, and given that this is CNS, that probably doesn't come as much of a shock. So now that you intend to examine the pipeline and truly shift how you look at it, to what extent does that shift play into any decision to move further into diversification beyond CNS? And assuming you mostly remain in CNS, in what way do you alter the probability of success for projects toward ones with lower risk? Given that management changes are also underway, and considering how supportive the board is, how do you accomplish all of this? I believe you grasp what I'm asking. Thank you.

Michel Vounatsos

executive
#26

Yes, definitely, and I'd say that's a really key thing to ask. The whole matter comes down to priorities being set correctly and finding a way to shift the risk profile of the portfolio back into balance. That much is clear to us. It relates to neuroscience, though Priya can elaborate further.

Priya Singhal

executive
#27

Absolutely, Marc — and that's a very relevant thing to bring up. I'd frame it as having two parts. First, science is what guides us, and we're staying inside neuroscience. At this stage I want to state plainly that neuroscience remains where we operate; it's central to what we know, to the people we have, and we keep strengthening that foundation. That said, we're certainly willing to explore nearby areas. We've shown that already — as I noted, through the zuranolone submission and the 104 data release right after it. Beyond that, we're active in lupus, which is a specialized area of immunology, and we might look at additional indications. We might also evaluate other possible opportunities in that space. That's one route by which we'd broaden and rebalance risk, since, as you're aware, the likelihood of technical and regulatory success shifts once you step outside neuroscience. Because neuroscience is our core strength and because of everything we've learned, we think we hold a great deal of asymmetrical knowledge there. Within that area, we keep raising and maximizing our odds of success — by deepening what we're already good at: biomarkers, clinical development, functional genomics, human validation. Those methodologies, we believe, are what will help us lift our chance of succeeding and enable us to deliver on proof of concepts. So it's a two-part strategy, and on top of that come the four pillars you're familiar with — biosimilars and digital health. We're also examining integration, correct, through digital options. This genuinely moves past a very limited focus. It considers the portfolio as a whole and the value it delivers as a whole. We have know-how when it comes to modalities; every modality is at our disposal. We examine targets, and we examine which modality fits best; we don't start with modalities and ask how to exploit them — we work the other direction. We start with the disease target and then determine the best modality to pursue. I hope that offers you some sense of our approach. Thank you.

Priya Singhal

executive
#28

Actually, let me add something here. May I simply speak to that final piece I intended to include, which you inquired about — namely, the way we'd approach this when sitting in a board context, in a management context. What I'd like to say is that I hold quite a bit of authority, as things stand right now, and decisions regarding prioritization are ones I'm making. My hope is that this continues moving forward.

Brian Abrahams

analyst
#29

Morning. I appreciate you taking my question, and I want to wish Michel well as he moves on. With some of the shifts in leadership and new efforts at the agency, what is your current read on where the FDA stands regarding accelerated approval for beta amyloid antibodies? I understand the FDA has concurred that Clarity AD might function as a confirmatory study after lecanemab gets accelerated approval, but could you make clear, in the event accelerated approval isn't granted, if that phase 3 would be sufficient by itself to back full approval, or would another study be required? Thanks.

Michel Vounatsos

executive
#30

Thanks for those remarks. Priya.

Priya Singhal

executive
#31

Appreciate it. Let me pull back for a moment, Brian, and make the point that the Accelerated Approval Pathway is an extremely, extremely stringent and science-driven regulatory route. It has been around for a number of years at this point, a number of products have gone through it, and a great many patients across the United States have gained from that access. I'm aware there is plenty of discussion out there, and I'm seeing the same things you are, but my view is that right now there is not going to be any kind of potential major overhaul at any point. Enhancements are possible, refinements of some sort are possible. I'm certain that can be the case for any regulatory route as additional learnings come in. My belief is that our confidence in the Accelerated Approval Pathway has not been rattled; it stays an essential means by which you can deliver products to patients who genuinely need them at present. That's point 1. Point 2, I would say that with Clarity AD, the approach has been — and I believe Eisai and we have stated this publicly, so I'm merely repeating it — that we have started the filing on the basis of the phase 2 study, as you're aware. That happens through the Accelerated Approval Pathway. There is agreement from the FDA, and Eisai has spoken about this publicly too, that Clarity AD could function as a confirmatory study. Now, on your question about what happens if Clarity AD is unclear or ambiguous — could they still be approved? Could we still be approved? Commenting on that strikes me as highly speculative. What I think would be a sensible path forward, contingent on the data, would be to hold that discussion with the FDA. The reason is that the science here is complicated, as we have observed, and what matters most, in my view, is to keep evaluating the science and the data as it comes out and to judge how strong the evidence is. That, I believe, is genuinely what will make the difference in this situation. Thank you.

Geoff Meacham

analyst
#32

Hi, everyone. I appreciate you taking the question. I'd like to move on to some other lecanemab-related inquiries, and I'm curious, from a strategic standpoint, how much does it matter to you folks to have a strong Alzheimer's pipeline? I mean, considering the infrastructure you've built on the R&D side, there are obviously things to be learned from Aduhelm, but what I really want to ask is whether there's a chance, or possibly an opportunity, to add other assets that would sit behind lecanemab and thereby broaden the Alzheimer's portion of your business?

Priya Singhal

executive
#33

Thanks. First off, I'd say our dedication to Alzheimer's disease hasn't changed. With lecanemab, we feel extremely fortunate and privileged to have had two A beta removal agents. As for aducanumab, we're still putting money into EMBARK and ENVISION. Our view is that these could generate scientific data of real importance that might affect not just our own product but the entire field; that continues to matter a great deal. We're still funding programs focused on early Alzheimer's disease. As I said earlier, BIIB080 is our anti-tau ASO, and BIIB113 is an OGA inhibitor. These represent quite distinct ways of targeting tau pathology. This is still very significant. We have additional assets whose pathways and targets haven't been named yet, and I'm not able to discuss them, but there are plenty of others too; our commitment to Alzheimer's disease stands. We're certainly absorbing every lesson, both in terms of the scientific method and in how we'd handle clinical development. We keep building up our clinical development know-how in this space. Would we consider bringing in other assets? Yes, we keep searching and examining possibilities outside the company. At any moment, we're evaluating numerous assets. Once again, as I've mentioned, science will point the way. Science and value will keep pointing the way. My answer is yes, we have real interest, and our dedication to Alzheimer's disease stays very strong. Thank you.

Jay Olson

analyst
#34

Hello, and thank you for allowing me to ask. I also want to express gratitude to Michel for the unwavering commitment he shows toward patients. What I'd like to know concerns the balance sheet. Should you decide to go after a bigger business development deal, what level of debt would you be prepared to assume? Thanks.

Michael McDonnell

executive
#35

Yes, Jay, this is Mike. I appreciate the question. From my perspective, if you take a look at the balance sheet, we're positioned quite well. At the close of the quarter, we held $4.8 billion in cash. Then in April, Samsung provided us with an additional $1 billion, which means we now have just under $6 billion in cash available. If you take a look at where our borrowing stands right now, gross debt sits at roughly two times EBITDA, while net debt is under one turn. Suppose, just as a hypothetical — I'm not suggesting this is something we'd do or avoid doing — that we layered on another turn of debt. That would give us somewhere around $8 billion of additional room. Our aim, I think, is to put that capacity to work in the most inventive way possible, with the top priority being a return to growth down the line. Over the past five and a half years, we've closed roughly 30 transactions and committed around $6.5 billion toward business development. Our focus is going to stay on growing the business while also giving money back to investors. There's going to be a trade-off there. I'd put it this way — sure, there's room for us to take on a bit more borrowing, but at the moment we're sitting on such a large pile of cash that piling on more debt isn't something we'd clearly require or pursue anytime soon. I hope that answers it.

Phil Nadeau

analyst
#36

Morning, and thanks for taking my question. This follows up on what Brian asked regarding the Clarity AD study. Could you go into somewhat more detail on how the trial was designed, especially regarding the statistical power for the primary endpoint, CDR sum of the boxes? On CDR-SB, what size of difference between drug and placebo would count as clinically meaningful? Then, regarding the P value, if this is only a single phase 3 study, which P value is needed to succeed? Would 0.05 be enough, or is 0.01 required? Thanks.

Priya Singhal

executive
#37

Thank you. To begin with Clarity AD — we haven't discussed the study's powering publicly, though Eisai has made comments about it. During the phase two study, we had multiple arms, and the outcome was not powered for CDR Sum of Boxes. That's quite a different situation. How phase three was designed has been informed by phase two, and it is powered to detect a statistically significant difference on CDR Sum of Boxes. That's one point I wanted to address. The second point is that we believe CDR Sum of Boxes is the correct primary endpoint for this patient population and for MCI and early Alzheimer's disease; it contains cognitive and functional elements. In our view, it is the most relevant primary endpoint, and we feel fairly confident in the study's design to deliver the outcome for us. Now, as for which kind of P value — that's very difficult. I would be speculating, so I won't speculate here. But we feel the study has been designed appropriately and that reviewing the results would be important. On clinical meaningfulness, I think we've done a great deal of work ourselves. There's plenty of external dialogue, and we honestly do believe that the EMERGE data we had, with the 22% difference, is highly clinically relevant and clinically meaningful to KOLs and to patients. We've done a lot of work around this and I'm sure you've seen that in the public domain. Beyond that, I don't think I can comment. Thank you.

Michael McDonnell

executive
#38

Operator, I think we have time for one final question.

Mohit Bansal

analyst
#39

Great. I appreciate you fitting me in. Perhaps this one's for Mike. I'm just attempting to get a handle on what you said regarding buybacks. Since the company's cash flow isn't as strong as it was a couple of years ago, and there may be a need for diversification or acquiring additional assets, why are share repurchases a priority on your list right now? Thank you.

Michael McDonnell

executive
#40

Yeah. Thanks for asking, Mohit. As you know, we didn't repurchase any shares in the quarter, and you shouldn't look at it quarter by quarter, since that can shift based on what business development activity we have going on, when windows open, other factors, and so forth. We do anticipate using part of the $2.8 billion still remaining over the rest of 2022. We still think our stock is a solid investment, yet at the same time, you clearly won't see us buying back shares at the rate you saw two, three, four years ago, given where things stand with Tecfidera and Rituxan; we keep viewing it as a good investment, and it will be a balance between BD and buybacks going forward; we'll be smart and balanced regarding it. Our capital allocation, as we said, is among our key operational priorities as we look ahead through the remainder of 2022. That brings today's call to a close. Thank you all for being with us.

Operator

operator
#41

Appreciate it. That brings an end to the conference call for today. We're grateful that all of you took part. Everyone, at this point you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.